Spago Nanomedical (Sweden) Insiders
| SPAGO Stock | SEK 0.22 0.02 10.00% |
Spago Nanomedical employs about 15 people. The company is managed by 4 executives with a total tenure of roughly 35 years, averaging almost 8.0 years of service per executive, having 3.75 employees per reported executive. Breaking down Spago Nanomedical's management performance can provide insight into the firm performance.
| Oskar MSc Insider Head VP |
| Paul Hargreaves Insider Chief Officer |
Spago |
Spago Nanomedical Management Team Effectiveness
The company has return on total asset (ROA) of (0.1241) % which means that it has lost $0.1241 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.2052) %, meaning that it generated substantial loss on money invested by shareholders. Spago Nanomedical's management efficiency ratios could be used to measure how well Spago Nanomedical manages its routine affairs as well as how well it operates its assets and liabilities.Spago Nanomedical Workforce Comparison
Spago Nanomedical AB is currently regarded as top stock in number of employees category among its peers. The total workforce of Biotechnology industry is at this time estimated at about 136. Spago Nanomedical retains roughly 15.0 in number of employees claiming about 11% of stocks in Biotechnology industry.
Spago Nanomedical Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Spago Nanomedical Price Series Summation is a cross summation of Spago Nanomedical price series and its benchmark/peer.
Spago Nanomedical Notable Stakeholders
A Spago Nanomedical stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Spago Nanomedical often face trade-offs trying to please all of them. Spago Nanomedical's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Spago Nanomedical's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Oskar MSc | Head VP | Profile | |
| Paul Hargreaves | Chief Officer | Profile | |
| Mats MSc | Chief Officer | Profile | |
| Hanna MSc | Chief Officer | Profile |
About Spago Nanomedical Management Performance
The success or failure of an entity such as Spago Nanomedical often depends on how effective the management is. Spago Nanomedical management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Spago management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Spago management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Spago Nanomedical AB develops nanomaterials for cancer diagnostics and treatment. Spago Nanomedical AB was founded in 2007 and is based in Lund, Sweden. Spago Nanomedical is traded on Stockholm Stock Exchange in Sweden.
Please note, the imprecision that can be found in Spago Nanomedical's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Spago Nanomedical AB. Check Spago Nanomedical's Beneish M Score to see the likelihood of Spago Nanomedical's management manipulating its earnings.
Spago Nanomedical Workforce Analysis
Traditionally, organizations such as Spago Nanomedical use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Spago Nanomedical within its industry.Spago Nanomedical Manpower Efficiency
Return on Spago Nanomedical Manpower
| Revenue Per Employee | 44K | |
| Revenue Per Executive | 165K | |
| Net Loss Per Employee | 2.6M | |
| Net Loss Per Executive | 9.8M |
Additional Tools for Spago Stock Analysis
When running Spago Nanomedical's price analysis, check to measure Spago Nanomedical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Spago Nanomedical is operating at the current time. Most of Spago Nanomedical's value examination focuses on studying past and present price action to predict the probability of Spago Nanomedical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Spago Nanomedical's price. Additionally, you may evaluate how the addition of Spago Nanomedical to your portfolios can decrease your overall portfolio volatility.